NEW YORK, March 23 (GenomeWeb News) - Structural Genomix and Serono will collaborate on developing drugs that target kinases and phosphatases, SGX said today.
Under the agreement, SGX will use its X-ray crystallography-based approach, called Fragments of Active Structures, to generate lead compounds against kinase and phosphatase targets provided by Serono. Geneva, Switzerland-based Serono will develop and commercialize drug candidates resulting from the collaboration.
In return, San Diego-based SGX will receive up to $68 million in upfront and research fees and milestone payments. In addition, it will obtain royalties from sales of drugs.
SGX's FAST approach combines screening of lead-like drug fragments using X-ray crystallography with computational design and chemical synthesis.